Johnson & Johnson (NYSE: JNJ) managed to marginally beat earnings expectations this Tuesday morning. This is the first of the consumer products and medical products companies to report, so this one could have a heavier impact depending on what is said.
The company beat earnings at $1.13 EPS and sales rose almost 4% to $16.25 billion; estimates were $1.09 EPS and $16.28 billion in sales from Thomson Reuters. The company noted that operational sales were up 4.0% and its negative currency impact was only 0.1% as domestic sales fell by 3.4% and international sales rose by just over 10% in the quarter.
For the Fiscal Year 2012, J&J sees earnings of $5.05 to $5.15 EPS and that is a bit shy of the $5.21 consensus target based upon operational growth of down slightly to as high as 5.5% and based upon a negative currency impact of around 2.5%.
J&J’s guidance is weighing on the stock. Shares are indicated down 0.75% at $64.50 against a 52-week trading range of $57.50 to $68.05 and versus a Thomson Reuters consensus price target of $73.00.
The report has remained better than many may have guessed considering all of the product problems before. Unfortunately, there is little driving force here that stands out as great opportunity.
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
